Cogent Biosciences, Inc. Accounts Payable
Cogent Biosciences, Inc. (COGT) had Accounts Payable of $7.49 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-10
- 2026-06-30: Accounts Payable, Current $7.49M.
- 2026-03-31: Accounts Payable, Current $13.74M.
- 2025-12-31: Accounts Payable, Current $9.50M.
- 2025-09-30: Accounts Payable, Current $16.03M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $7.49M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $13.74M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $9.50M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $16.03M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $16.63M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $14.15M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $12.01M 10-K · filed 2026-02-17 |
| 2024-09-30 | $15.06M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $8.97M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $15.56M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $10.65M 10-K · filed 2025-02-25 |
| 2023-09-30 | $9.87M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $7.16M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $4.17M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $5.84M 10-K · filed 2024-02-26 |
| 2022-09-30 | $4.09M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $3.49M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $4.01M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $3.48M 10-K · filed 2023-03-14 |
| 2021-09-30 | $4.35M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $1.99M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $315.00K 10-Q · filed 2021-05-12 |
| 2020-12-31 | $732.00K 10-K · filed 2022-03-15 |
| 2020-09-30 | $639.00K 10-Q · filed 2020-11-09 |
| 2020-06-30 | $632.00K 10-Q · filed 2020-08-11 |
| 2020-03-31 | $628.00K 10-Q · filed 2020-05-11 |
| 2019-12-31 | $3.18M 10-K · filed 2021-03-16 |
| 2019-09-30 | $1.59M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $1.66M 10-Q · filed 2019-08-12 |
| 2019-03-31 | $1.84M 10-Q · filed 2019-05-13 |
| 2018-12-31 | $1.52M 10-K · filed 2020-03-26 |
| 2018-09-30 | $803.00K 10-Q · filed 2018-11-13 |
| 2018-06-30 | $1.66M 10-Q · filed 2018-08-13 |
| 2018-03-31 | $3.08M 10-Q · filed 2018-05-14 |
| 2017-12-31 | $1.35M 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |